New crystal form of BTK inhibitor, and preparation method thereof

The invention relates to a novel crystal form of a BTK inhibitor, and a preparation method thereof. Specifically, the invention relates to an A type crystal of N-(3-((6-(4-((4, 4-difluoropiperidin-1-yl)methyl)phenyl)-7H-pyrrolo[2, 3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide hydrochloride. The preparation method comprises the following steps: preparing hydrochloride from N-(3-((6-(4-((4, 4-difluoropiperidin-1-yl)methyl)phenyl)-7H-pyrrolo[2, 3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide in an organic solvent, and crystallizing, thereby obtaining the product. The novel crystal form of the BTK inhibitor can be used for modulating Bruton kinase (BTK) activity and for treating and/or preventing diseases related to BTK activity. 本发明涉及一种BTK抑制剂的新晶型及其制备方法。具体而言，本发明涉及N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯[2,3-d]并嘧啶-4-基)氧基)苯基)丙烯酰胺盐酸盐的A型结晶。其通过将N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯[2,3-d]并嘧啶-4-基)氧基)苯基)丙烯酰胺在有机溶剂中制成盐酸盐并析晶获得。其可以用于调节Bruton激酶(BTK)活性并且用于治疗和/或预防与BTK活性相关的疾病。